BioTime (BTX) Announces Quarterly Results
BioTime (NYSE:BTX) issued its quarterly earnings data on Tuesday. The company reported ($0.16) EPS for the quarter, StockRatingsNetwork reports. The company had revenue of $300.08 million for the quarter, compared to the consensus estimate of $362.25 million.
Shares of BioTime (NYSE:BTX) opened at 2.84 on Tuesday. BioTime has a 1-year low of $2.21 and a 1-year high of $4.18. The stock has a 50-day moving average of $2.79 and a 200-day moving average of $3.04. The company’s market cap is $167.8 million. BioTime also saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 5,226,508 shares, a growth of 4.5% from the July 15th total of 5,002,728 shares. Approximately 9.3% of the company’s stock are sold short. Based on an average trading volume of 166,767 shares, the days-to-cover ratio is currently 31.3 days.
BioTime, Inc is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (NYSE:BTX) cell lines, and royalties from Hextend.
Receive News & Ratings for BioTime Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.